9L rat glioma cells have been used as a model for brain tumor therapies. It has been reported that in vivo infection of 9L cells with a replication-defective retrovirus expressing the herpes simplex thymidine kinase gene resulted in decreased tumor formation following treatment with the antiviral drug ganciclonr. the study reported here, rats were injected either intracerebrally or subcutaneously with 9L glioma cells expressing a chimeric hygromycin phosphotransferase-thymidine kinase fusion protein or with unmodified 9L cells. Tumor formation was decreased in the rats receiving modified cells, even in the absence of treatment with gacc vir. Suppression of tumor growth was also observed with cells modified to express the intracellular selectable marker neomycin phosphotransferase. These results indicate that an intracellular selectable marker, in the absence of pharmacologic selection, can inhibit tumor growth of 9L cells. The demonstration that intracellular marker genes can negatively influence the survival of transplanited cells has important implications for in vivo studies that use genetically modified cells.
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The median survival ofpatients with a malignant glioma is x1 year following diagnosis, even with aggressive surgery, radiation therapy, and chemotherapy (1) . New treatment regimens for gliomas are frequently tested in animal models, often using the 9L rat glioma cell line. Several reports have used retroviral vectors to demonstrate in vivo transduction of C6 or 9L gliosarcoma tumors (2) (3) (4) (5) . Culver et al. (2) reported the effective treatment of an experimentally implanted 9L rat glioma by infection with a retrovirus conferring sensitivity to the drug ganciclovir. The investigators demonstrated that intracranially implanted 9L cells could be infected with a replication-defective retrovirus expressing the herpes simplex virus thymidine kinase (tk) gene following injection of the tumor with the viral packaging cell line. All animals were treated with ganciclovir, and 11 of 14 animals that received the virus-producing packaging cell line did not develop tumors in the 15-day observation period prior to sacrifice. Subsequent studies extended these findings and demonstrated that ganciclovir treatment was necessary for the prevention of tumor formation during the first 3 weeks after cell injection (3). These results and related studies (4) (5) (6) (7) have provided the basis for human trials in which intratumor injection of a packaging cell line that produces an amphotropic retrovirus expressing the tk gene is followed by treatment with ganciclovir (8) . We have attempted to reproduce the findings of Culver et al. (2) (10) . The plasmid tgCMV/HyTK contains an expression cassette (CMV-HyTK, Fig. 1 ) that consists of a human cytomegalovirus (CMV) immediate early promoter followed by a cDNA encoding an Hph-Tk fusion protein followed by a SV40 early-region polyadenylylation signal (9) . CMVHyTK, LHy, and LHyTK were generous gifts from Targeted Genetics (Seattle, WA).
Cell Culture. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum without antibiotics. 9L cells were obtained from G. Steen (11) . PA317 cells have been described (12) . The PA317/LHy and PA317/LHyTK packaging cell lines used to produce the retroviral vectors LHy and LHyTK, respectively, were gifts from Targeted Genetics. Procedures for calcium phosphatemediated cell transfection and retroviral vector production and use were as described (13 Statistics. Tumor size in rats that received subcutaneous tumor cell injections was compared by using the WilcoxonMann-Whitney rank sum test because ofthe small sample size and lack of a valid assumption for a normal distribution (16) .
RESULTS

Generation and Testing of Vectors That Confer Gancilovir
Sensitivity. For these experiments we used the LHyTK retroviral vector (Fig. 1 ) that encodes a chimeric Hph-Tk fusion protein (9) . The use of a fusion protein virtually guarantees that selection for the dominant hph marker will result in expression of the tk marker as well, which is not always the case for vectors having two protein coding sequences expressed from different promoters. PA317 amphotropic retrovirus packaging cell lines that produced the LHyTK vector or a vector that encodes only Hph (LHy; Fig.  1 ) were generated by a transfection/infection technique (13) . Both vectors had a titer of about 106 hygromycin-resistant colony-forming units/ml with NIH 3T3 cells as targets for infection (data not shown).
To test the ability of the LHyTK vector to confer ganciclovir sensitivity, we transduced 9L gliosarcoma cells with the LHy and LHyTK vectors, selected the cells in hygromycin (400 Aug/mi), and measured survival of pooled populations (>500 clones each) following exposure to various concentrations ofganciclovir. A 50%6 reduction in growth rate of 9L/LHyTK cells occurred with ganciclovir at 0.05 pg/ml, whereas 9L and 9L/LHy cells were unaffected by doses up to 30 pg/ml ( Fig. 2 and data not shown). Survival of 9L/ LHyTK cells was reduced 99% by treatment with ganciclovir at 1 pg/ml for 1 week (Fig. 2) . These results confirm the ability of the LHyTK vector to confer high sensitivity to ganciclovir toxicity which is at least as effective as in previous reports (2, 3, 7) .
Expression of retroviral vectors in cells can diminish with time or the vector can be lost entirely. However, the occurrence of ganciclovir-resistant 9L/LHyTK cells was low (<0.2%) as measured by colony formation in medium containing ganciclovir at 0.3-30 pg/ml (data not shown). In these experiments, the cells were plated at low density (104 cells per 6-cm dish) so that a bystander effect should be small. To Ganciclovir (ptg/ml) (Fig. 4A) , consistent with previous reports (2) (3) (4) (5) (6) . However, in the absence of ganciclovir treatment, the 9L/HyTK cells formed significantly smaller tumors than the unmodified 9L cells (Fig. 4B) In addition, expression of the neo gene instead of the hph-tk gene was also associated with decreased tumor growth (LXSN plasmid, Table 1 ). At 18 days, only four ofthe five animals showed tumor growth, and at 49 days the mean tumor volume was significantly less than in a mock-infected control (9L/PA317 supernatant). This result indicates that the growth inhibition is not specific to the LHyTK vector but is seen following transfection of other selectable markers.
In contrast to decreased tumor growth in animals, in vitro assays of cell growth showed no difference between the 9L cells and modified 9L cells. Specifically, 9L, 9L/LHyTK infected, 9L/LHyTK transfected, 9L/CMV-HyTK transfected, and 9L/LXSN transfected cells were seeded at 104 cells per 6-cm dish and cells were counted in duplicate dishes at 3, 5, and 7 days after seeding. There was no significant difference in the cell doubling times, which ranged from 27 to 31 hr (data not shown). (15) *, Group differed from the control (9L unmodified, no GCV) at the 95% confidence level by the Wilcoxon-Mann-Whitney rank sum test; **, group differed from the 9L/PA317 supernatant control group at 95% confidence level. a9L, unmodified; 9L/LHyTK virus, infected with LHyTK (hph/tk-expressing) virus; 9L/LHyTK plasmid, transfected with plasmid used to produce LHyTK virus; 9L/CMV-HyTK plasmid, transfected with a plasmid expressing hph/tk from the CMV promoter; 9L/LXSN plasmid, transfected with pLXSN plasmid expressing neo; 9L/PA317 supernatant, cells were exposed in the presence of Polybrene (4 yg/ml) and at low density with 1 ml of medium conditioned by PA317 packaging cells at 12-to 24-hr intervals for a total of 10 exposures.
bMale Fischer 344 rats were anesthetized with phenobarbital and injected subcutaneously with 5 x 105 cells.
CMaximum length (L), width (W), and height (H) ofthe tumor were measured twice per week and the volume was calculated as (4/3 x ff x L x W x H)/8. Note that the volumes differ from those in Fig. 4 (2) was developed by Genetic Therapy (Gaithersburg, MD) and was produced by using PA317 cells (12) . We requested, but were unable to obtain, the vector-producing cells for the purpose of reproducing the study of Culver et al. (2) . We have shown that cell transduction with the LHyTK virus used here makes the cells at least as sensitive to ganciclovir as transduction by other published vectors that express tk, but we cannot be sure that some poorly defined property of the vectors is important for the previously observed antitumor effects. Finally, the dose of ganciclovir used in this study is less than that used in one of the previous studies (150 mg/ml twice daily; ref.
2), since we found that at this dose three of five otherwise untreated rats died, suggest- ing that this dose is near the LD50 for Fischer 344 rats. However, the dose used here is comparable to that used in subsequent studies (3, 7) .
The main conclusion of this work is that intracellular transgenes can profoundly affect the survival of 9L cells following transplantation. The most likely reason is that the expression of the novel protein enhances the immune response against the tumor, although we have not demonstrated that the effect of the transgene is directly mediated by an immune response. The broader implication of the study is that the introduction of foreign genes-including selectable markers such as tk, neo, and hph-may modulate the immune response to recipient cells. We have demonstrated that this can result in rejection of a syngeneic, although still immunogenic, cell line. It remains to be determined whether nonimmunogenic transplants are similarly affected, and whether these effects can be harnessed for the treatment of human tumors.
